Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.920 +0.100 (+1.13%)
Streaming Delayed Price Updated: 10:33 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,912
Open 9.030
Bid (Size) 8.900 (5)
Ask (Size) 8.940 (2)
Prev. Close 8.820
Today's Range 8.750 - 9.170
52wk Range 4.810 - 13.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming
Federal support for psychedelics is rising fast. One biotech CEO explains what it means for clinical trials, access, and real-world therapy. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-5.2%
-5.2%
1 Month
+29.8%
+29.8%
3 Month
-1.0%
-1.0%
6 Month
-16.2%
-16.2%
1 Year
-32.9%
-32.9%

More News

Read More
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Via Benzinga
Topics Government
Exposures Political
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
Via Investor Brand Network
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
Via Investor Brand Network
Exposures Product Safety
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
InvestorkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
Via Investor Brand Network
Exposures Product Safety
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
Via Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at Milken Global Conference on Medical Breakthroughs
Via Investor Brand Network
Cybin to Participate at the 28th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
Via Investor Brand Network
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Forms Strategic Partnership With Osmind to Prepare for Mental Health Drug Commercialization
Via Investor Brand Network
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
From Cybin Inc.
Via Business Wire
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
Via Investor's Business Daily
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
Via Investor Brand Network
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire

Frequently Asked Questions

Is Cybin Inc. Common Shares publicly traded?
Yes, Cybin Inc. Common Shares is publicly traded.
What exchange does Cybin Inc. Common Shares trade on?
Cybin Inc. Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Cybin Inc. Common Shares?
The ticker symbol for Cybin Inc. Common Shares is CYBN on the New York Stock Exchange
What is the current price of Cybin Inc. Common Shares?
The current price of Cybin Inc. Common Shares is 8.920
When was Cybin Inc. Common Shares last traded?
The last trade of Cybin Inc. Common Shares was at 06/06/25 10:33 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback